skip to main content

NSCLC — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardLung CancerNSCLCSCE Medical Oncology

A patient with untreated metastatic non-squamous NSCLC has PD-L1 TPS 55%, no EGFR or ALK alteration, ECOG 0 and low-volume asymptomatic disease. If pembrolizumab monotherapy is chosen under NICE TA531, which treatment-limit statement is correct?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Stop after 2 years of uninterrupted treatment, or earlier at disease progression

TA531 recommends pembrolizumab monotherapy for untreated metastatic NSCLC with PD-L1 TPS at least 50% and no EGFR- or ALK-positive mutation, subject to stopping after 2 years of uninterrupted treatment or earlier progression. The metastatic appraisal does not impose a 1-year adjuvant cap, serial PD-L1 testing is not the stopping rule, and the recommendation does not authorise indefinite or automatic retreatment.

Reference: NICE TA531 pembrolizumab for untreated PD-L1-positive metastatic NSCLC (Published July 2018): https://www.nice.org.uk/guidance/ta531/chapter/1-Recommendation